Table 25. The inhibitory effect of compounds (28, 30) on formation of nitric oxide in medium



Cell line: Raw 264.7 cells Inducer: LPS (1 μg/ml)

Cell line: N9 cells Inducer: LPS (10 ng/ml)+ IFN-? (10 U/ml)

No.	Conc. (μM)	R_2'	R_4"	Nitric oxide formation (μM)			
				RAW	% inhibition	N9	% inhibition
	Control			44.8±0.1		38.2±0.1	
28	3	Cl	F	--	--	33.4±0.7	12.6±1.9
	10			49.6±0.5	-10.2±1.4	32.8±0.3	14.1±0.9
	30			50.3±0.4	-12.1±1.4	**Cytotoxic**	
30	3	Cl	H	--	--	33.8±0.5	11.6±1.5
	10			48.2±1.2	-7.5±2.3	32.3±0.2	15.5±0.6
	30			50.5±0.4	-12.7±1.2	**Cytotoxic**	
1400W							
	1			35.8±2.1**	20.0±5.5**	23.7±0.9**	37.9±2.3**
	3			20.8±0.5**	53.2±1.1**	16.2±0.7**	57.6±1.9**
	10			8.7±0.3**	80.2±0.8**	12.1±0.3**	68.2±0.7**
	IC_{50}			**2.9±0.2 μM**		**2.2±0.1 μM**	

* $P < 0.05$, ** $P < 0.01$; N = 3; --, not determined

N-(3-Aminomethyl)benzylacetamidine (1400W): positive control

Table 26. The inhibitory effect of compounds (31-33, 35-37, 39, 40) on formation of nitric oxide in medium



Cell line: Raw 264.7 cells Inducer: LPS (1 μg/ml)

Cell line: N9 cells Inducer: LPS (10 ng/ml)+ IFN-? (10 U/ml)

No.	Conc. (μM)	R_6	R_2'	Nitric oxide formation (μM)			
				RAW	% inhibition	N9	% inhibition
	Control			44.8±0.1		38.2±0.1	
31	10	Cl	F	42.1±1.0	6.1±2.6	36.3±1.0	4.9±2.7
	30			44.9±0.8	-0.2±1.5	31.9±0.3	16.4±0.7
32	10	Cl	Cl	42.5±0.2	5.1±0.6	33.0±0.2	13.5±0.8
	30			44.7±0.1	0.2±0.4	28.6±0.5**	25.1±1.5**
33	10	Cl	OCH_3	42.7±0.9	4.6±1.9	39.9±0.5	-4.2±1.6
	30			43.9±1.0	2.1±2.0	39.0±0.9	-2.0±2.1
35	10	F	F	43.9±0.2	1.9±0.7	41.3±0.7	-7.9±1.8
	30			43.9±0.7	1.9±2.1	39.3±0.4	-2.7±1.0
36	10	F	Cl	44.9±1.1	-0.07±2.0	41.2±1.1	-7.7±3.0
	30			46.5±0.2	-3.7±0.5	34.7±0.5	9.1±1.6
37	10	F	OCH_3	45.2±0.4	-0.9±1.3	30.3±0.3	20.5±1.1
	30			45.9±0.6	-2.5±1.9	31.8±0.4	16.6±0.9
39	10	OCH_3	F	40.1±1.0	10.4±2.0	36.1±0.6	5.6±1.9
	30			40.5±0.6	9.5±1.7	35.3±1.1	7.6±3.1
40	10	OCH_3	Cl	42.0±0.5	6.3±0.9	34.8±0.1	9.0±0.3
	30			38.2±1.8	14.7±4.3	31.9±1.0	16.4±2.7
1400W							
	1			35.8±2.1**	20.0±5.5**	23.7±0.9**	37.9±2.3**
	3			20.8±0.5**	53.2±1.1**	16.2±0.7**	57.6±1.9**
	10			8.7±0.3**	80.2±0.8**	12.1±0.3**	68.2±0.7**
	IC_{50}			**2.9±0.2 μM**		**2.2±0.1 μM**	

* $P < 0.05$, ** $P < 0.01$; N = 3

N-(3-Aminomethyl)benzylacetamidine (1400W): positive control

Table 27. The inhibitory effect of compounds (43, 44) on formation of nitric oxide in medium



Cell line: Raw 264.7 cells Inducer: LPS (1 μg/ml)

Cell line: N9 cells Inducer: LPS (10 ng/ml)+ IFN-? (10 U/ml)

No.	Conc. (μM)	R_6	R_2'	Nitric oxide formation (μM)			
				RAW	% inhibition	N9	% inhibition
	Control			44.8±0.1		38.2±0.1	
43	1	F	F	--	--	26.9±1.1**	29.6±2.8**
	3			--	--	**Cytotoxic**	
	10			37.2±1.8*	17.0±3.8*	**Cytotoxic**	
	30			33.2±0.7**	25.9±1.4**	**Cytotoxic**	
44	1	OCH_3	Cl	--	--	27.9±0.7**	26.9±1.8**
	3			--	--	**Cytotoxic**	
	10			35.4±0.9**	21.0±1.7**	**Cytotoxic**	
	30			30.6±1.2**	31.6±2.8**	**Cytotoxic**	
1400W							
	1			35.8±2.1**	20.0±5.5**	23.7±0.9**	37.9±2.3**
	3			20.8±0.5**	53.2±1.1**	16.2±0.7**	57.6±1.9**
	10			8.7±0.3**	80.2±0.8**	12.1±0.3**	68.2±0.7**
	IC_{50}			**2.9±0.2 μM**		**2.2±0.1 μM**	

* $P < 0.05$, ** $P < 0.01$; N = 3; --, not determined

N-(3-Aminomethyl)benzylacetamidine (1400W): positive control

Table 28. The inhibitory effect of compounds (45-47, 49-51, 53, 54) on formation of nitric oxide in medium



Cell line: Raw 264.7 cells Inducer: LPS (1 μg/ml)

Cell line: N9 cells Inducer: LPS (10 ng/ml)+ IFN-? (10 U/ml)

No.	Conc. (μM)	R_6	R_2'	Nitric oxide formation (μM)			
				RAW	% inhibition	N9	% inhibition
	Control			44.8±0.1		38.2±0.1	
45	10	Cl	F	43.9±1.5	1.9±3.0	36.7±2.5	4.0±6.7
	30			49.6±0.4	-10.7±1.4	39.5±0.2	-3.4±0.6
46	10	Cl	Cl	45.6±0.6	-1.8±1.9	39.2±0.9	-2.5±2.4
	30			47.0±1.0	-4.8±2.6	40.1±1.3	-4.8±3.7
47	10	Cl	OCH_3	44.8±0.5	0.00±0.9	37.6±0.4	1.5±1.1
	30			43.3±1.0	3.3±2.6	38.1±1.0	0.3±3.0
49	10	F	F	45.6±0.4	-1.6±0.6	40.1±0.7	-4.9±2.0
	30			43.7±0.8	2.5±2.3	42.4±0.3	-10.8±1.0
50	10	F	Cl	46.5±0.5	-3.7±0.9	36.7±1.5	4.1±4.2
	30			47.1±0.2	-5.2±0.8	38.1±0.6	0.3±1.7
51	10	F	OCH_3	41.1±0.6	8.2±1.5	36.7±0.9	3.8±2.2
	30			44.9±0.4	-0.08±0.5	37.6±1.1	1.6±3.0
53	10	OCH_3	F	38.6±0.9	13.9±2.4	38.9±0.5	-1.9±1.2
	30			38.6±0.7	13.8±2.0	36.0±0.6	5.8±1.5
54	10	OCH_3	Cl	39.2±0.7	12.4±2.1	37.1±0.1	2.9±0.2
	30			39.1±1.0	12.7±2.6	35.4±1.1	7.4±2.8
1400W							
	1			35.8±2.1**	20.0±5.5**	23.7±0.9**	37.9±2.3**
	3			20.8±0.5**	53.2±1.1**	16.2±0.7**	57.6±1.9**
	10			8.7±0.3**	80.2±0.8**	12.1±0.3**	68.2±0.7**
	IC_{50}			**2.9±0.2 μM**		**2.2±0.1 μM**	

* $P < 0.05$, ** $P < 0.01$; N = 3

N-(3-Aminomethyl)benzylacetamidine (1400W): positive control